--- title: "Hong Kong Stock Movement: Asymchem rises 15.03%: Orders surge 54% igniting CRO market" type: "News" locale: "en" url: "https://longbridge.com/en/news/296855672.md" description: "Asymchem rose 15.03%; CSPC Pharmaceutical Group fell 1.60%, with a transaction volume of HKD 464 million; Heng Rui Medicine fell 0.47%, with a transaction volume of HKD 189 million; China National Pharmaceutical Group fell 0.18%, with a transaction volume of HKD 148 million; Hansoh Pharmaceutical rose 0.90%, with a market value of HKD 190.1 billion" datetime: "2026-08-25T03:47:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296855672.md) - [en](https://longbridge.com/en/news/296855672.md) - [zh-HK](https://longbridge.com/zh-HK/news/296855672.md) generator: "portal-rs" --- # Hong Kong Stock Movement: Asymchem rises 15.03%: Orders surge 54% igniting CRO market **Hong Kong Stock Movement** Asymchem rose 15.03%. Based on recent key news: 1. On August 24, Asymchem released its interim results, with revenue increasing by 13.13% year-on-year, but net profit decreased by 15.71%. Despite the profit decline, significant growth in strategic emerging business revenue drove the stock price up. Source: Zhitong Finance 2. On August 24, Caixin reported that Asymchem's total order amount increased by 53.77% year-on-year, with new signed orders growing by 54.59%, and expected annual revenue growth of 19%-22%. The increase in order expectations boosted market confidence, leading to a rise in stock price. Source: Caixin 3. On August 25, Huayuan Securities expressed an optimistic view on the pharmaceutical sector, believing that the CDMO industry's performance certainty is high, enhancing investor confidence and driving stock prices up. Source: Huayuan Securities, the pharmaceutical sector is highly prosperous, with significant capital inflow. **Stocks with High Trading Volume in the Industry** Stone Pharmaceutical fell 1.60%. Based on recent key news: 1. On August 24, Stone Pharmaceutical recorded a cross-trade of 3.778 million shares, with a price of 9.368 HKD per share, up 1.9% from the previous closing price, involving 35.39 million HKD. The current price rose by 2%, reported at 9.37 HKD, with a trading volume of 89.65 million shares and a transaction amount of 840 million HKD, with a buy-sell ratio of 51:49, and a net active buy of 16.59 million HKD. 2. On August 24, Daiwa released a research report stating that Stone Pharmaceutical's interim revenue increased by 40.1% year-on-year to 18.59 billion RMB, with a net profit of 6.1 billion RMB, in line with profit forecast ranges and the bank's expectations, mainly driven by licensing fee income. During the period, product sales revenue increased by 4.1% year-on-year to 12.7 billion RMB, continuing the growth trend from the first quarter, with the target price raised from 11 HKD to 11.2 HKD, maintaining a "Buy" rating. 3. On August 22, both CLSA and Citi maintained a "Buy" rating for Stone Pharmaceutical, with target prices of 19 HKD and 14 HKD, respectively. Stone Pharmaceutical's interim revenue grew by 40.1%, and net profit increased by 139%. Hengrui Medicine fell 0.47%. Based on recent news: 1. On August 25, Hengrui Medicine announced that its HRG2010 capsule drug application for marketing authorization was accepted by the National Medical Products Administration. The intended indication for this drug is Parkinson's disease, with a cumulative R&D investment of approximately 84.2 million RMB. This news had a somewhat positive impact on the stock price but did not reverse the overall downward trend. 2. On August 24, Hengrui Medicine recorded a large pre-market transaction of 739,500 shares, with a transaction price 0.16% lower than the previous closing price, involving a total of 35.587 million HKD. The large transaction indicated a weakening market confidence in the stock, leading to a price decline. 3. On August 24, imported multinational pharmaceutical companies continued to penetrate the domestic market, and Hengrui Medicine's traditional market advantages continued to weaken, with the effectiveness of its internationalization strategy falling short of expectations. In the first half of the year, overseas licensing revenue declined by nearly 30% year-on-year, and the shortcomings of a large but weak R&D pipeline further amplified competitive disadvantages in the industry, leading to a decline in investor confidence in the capital market and putting pressure on the stock price Industry competition is intensifying, and internationalization progress is slow. China National Pharmaceutical Group fell 0.18%. Based on recent news, 1. On August 21, the national Class 1 innovative drug TQF6422 injection, independently developed by China National Pharmaceutical Group's subsidiary Zhengda Tianqing, was approved by the Center for Drug Evaluation of the National Medical Products Administration of China to conduct clinical research, intended for weight management in adult obese patients or overweight patients with at least one weight-related comorbidity. This news had a positive impact on the stock price but failed to offset the overall market pressure. 2. On August 24, the management of China National Pharmaceutical Group stated during an event speech that artificial intelligence can not only assist in research and development but also help companies save costs and unleash potential. Although this news indicates the company's future development potential, it did not immediately boost the stock price. 3. On August 23, Nomura published a report indicating that China National Pharmaceutical Group's performance in the first half of the year was strong, with revenue growing 10.6% year-on-year and net profit rising 1.4% year-on-year on a high base, both exceeding market expectations. Despite the good performance, the market's downward revision of future revenue forecasts affected stock price performance. The overall market performance is weak, and capital flows are unstable. **Stocks ranked among the top in industry market capitalization** Hansen Pharmaceutical rose 0.90%. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no\_news ### Related Stocks - [06821.HK](https://longbridge.com/en/quote/06821.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) ## Related News & Research - [Asymchem Laboratories announces extraordinary general meeting](https://longbridge.com/en/news/294528537.md) - [10:30 ETAsymchem's Dunhua 2 Carbapenem Manufacturing Site Successfully Completes its First FDA Inspection for Continuous Manufacturing of an API](https://longbridge.com/en/news/293770465.md) - [Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea](https://longbridge.com/en/news/296784834.md) - [10:57 ETViva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth](https://longbridge.com/en/news/297064309.md) - [GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability](https://longbridge.com/en/news/296439475.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**